Compare FSFG & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | FSFG | MOLN |
|---|---|---|
| Founded | 2008 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Savings Institutions | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 221.5M | 164.2M |
| IPO Year | 2008 | 2021 |
| Metric | FSFG | MOLN |
|---|---|---|
| Price | $32.09 | $4.30 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 1 |
| Target Price | ★ $31.50 | $3.75 |
| AVG Volume (30 Days) | ★ 18.1K | 4.4K |
| Earning Date | 01-27-2026 | 02-11-2026 |
| Dividend Yield | ★ 2.00% | N/A |
| EPS Growth | ★ 67.68 | N/A |
| EPS | ★ 3.32 | N/A |
| Revenue | ★ $84,223,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $999.99 |
| P/E Ratio | $9.63 | ★ N/A |
| Revenue Growth | ★ 23.59 | N/A |
| 52 Week Low | $21.63 | $3.36 |
| 52 Week High | $33.35 | $5.91 |
| Indicator | FSFG | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 48.18 | 50.88 |
| Support Level | $32.06 | $4.16 |
| Resistance Level | $32.85 | $4.44 |
| Average True Range (ATR) | 0.40 | 0.17 |
| MACD | -0.19 | -0.01 |
| Stochastic Oscillator | 10.63 | 55.90 |
First Savings Financial Group Inc provides various banking services to individuals and business customers in southern Indiana. The bank accepts deposits from the general public & uses those funds, along with other borrowings, mainly to originate a residential mortgage, commercial mortgage, construction, commercial business, & consumer loans, and to a lesser extent, to invest in mortgage-backed securities and other debt securities. The company conducts lending and deposit activities mainly with individuals and small businesses in its market area. The bank operates in two segments: core banking, which accounts for the majority of revenue, and SBA lending.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.